Evidence map›Paper›PMID 40904496›Full record

ArticleFrontiers in oncology2025

Assessing the diagnostic accuracy of unilateral systematic biopsy combined with targeted biopsy.

Qiyou Wu, Chunlei He, Xiang Tu, Bo Chen, Jinjiang Jiang, Jinbao Wang, Zhouhaoran Chen, Ruoxuan Liu, Qiaoxue Huang, Bo Tang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Qiyou Wu *Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Chunlei He *Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xiang Tu *Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Bo ChenDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Jinjiang JiangDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Jinbao WangDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Zhouhaoran ChenWest China School of Medicine, Sichuan University, Chengdu, Sichuan, China.
Ruoxuan LiuWest China School of Medicine, Sichuan University, Chengdu, Sichuan, China.
Qiaoxue HuangDepartment of Nursing, Xiufeng Community Health Service Center, Guilin, Guangxi, China.
Bo TangDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Jin YaoDepartment of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Qiang WeiDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: To evaluate unilateral systematic biopsy (SB) combined with targeted biopsy (TB) and assess its diagnostic accuracy in a real-world, single-centre setting. Methods: Patients with ≥1 MRI lesion who underwent both transperineal 12-core and 3-core TB were enrolled in this study. Detection rates for total prostate cancer (PCa) and clinically significant PCa (csPCa) were compared between TB, unilateral SB+TB, and SB+TB. Pathological consistency was assessed using the kappa test, and logistic regression was used to identify potential predictors. Results: A total of 250 men were enrolled, of which 126 (50.4%) and 103 (41.2%) exhibited total PCa and csPCa, respectively. Compared to SB+TB, ipsilateral SB combined with TB (ips-SB+TB) had a comparable csPCa detection rate (99/250 vs 103/250, p=0.125), while fewer clinically insignificant PCa were detected (17/250 vs 23/250, p=0.031). In addition, ips-SB+TB demonstrated superior sensitivity for csPCa (96.1%) with an AUC of 0.98. The ips-SB+TB had a significantly higher positive core rate than SB+TB (472/2244 vs. 563/3744, p<0.001). Moreover, ips-SB+TB also had a high consistency of Gleason grade compared to SB+TB (Kappa=0.89). In the multi-lesion cohort, ips-SB+TB also had a comparable csPCa detection rate compared to SB+TB (63/128 vs. 67/128, p=0.125). Conclusions: In conclusion, our study showed that ips-SB+TB was comparable to SB+TB in detecting csPCa. The results of this study provide valuable insight into the potential of ips-SB+TB as an alternative to SB+TB.

Indexed as

multiparametric magnetic resonance imaging utilizationprostate biopsyprostate cancerregional biopsyunilateral index lesion

Identifiers

PMID40904496
PMCPMC12401680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.